A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 40
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Amyotrophic Lateral Sclerosis (ALS) or Alzheimer's Disease (AD). It studies how the investigational drug MP-101 affects laboratory signs of the disease.

Age

18 years or older

Sex

All sexes can join

Main reasons for not taking part

• Healthy volunteers cannot join

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details